Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-020-78029-3 http://scihub22266oqcxt.onion/10.1038/s41598-020-78029-3 33262433!7708981!33262433     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Rep 2020 ; 10 (1): 20958 Nephropedia Template TP {{tp|p=33262433|t=2020. High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment |pdf=|usr=}}{{33262433}} gab.com Text High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=33262433 #FOAvip The impact of drug-drug interactions (DDI) between ritonavir-boosted lopinavir (LPV-r) to treat patients with coronavirus disease 2019 (COVID-19) and commonly used drugs in clinical practice is not well-known. Thus, we evaluated the rate and severity of DDI between LPV-r for COVID-19 treatment and concomitant medications. This was a cross-sectional study including all individuals diagnosed of SARS-CoV-2 infection treated with LPV-r and attended at a single center in Southern Spain (March 1st to April 30th, 2020). The frequency [95% confidence interval (95% CI)] of potential and major DDI were calculated. Overall, 469 patients were diagnosed of COVID-19, 125 (27%) of them were prescribed LPV-r. LPV-r had potential DDI with concomitant medications in 97 (78%, 95% CI 69-85%) patients, and in 33 (26%, 95% CI 19-35%) individuals showed major DDI. Twelve (36%) patients with major DDI and 14 (15%) individuals without major DDI died (p = 0.010). After adjustment, only the Charlson index was independently associated with death [adjusted OR (95% CI) for Charlson index >/= 5: 85 (10-731), p < 0.001]. LPV-r was discontinued due to side effects in 31 (25%) patients. Management by the Infectious Diseases Unit was associated with a lower likelihood of major DDI [adjusted odds ratio (95% CI): 0.14 (0.04-0.53), p = 0.003). In conclusion, a high frequency of DDI between LPV-r for treating COVID-19 and concomitant medications was found, including major DDI. Patients with major DDI showed worse outcomes, but this association was explained by the older age and comorbidities. Patients managed by the Infectious Diseases Unit had lower risk of major DDI. Twit Text FOAVip High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=33262433 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33262433 #FOAvip English Wikipedia <ref>{{Cite pmid|33262433}}</ref> High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment #MMPMID33262433 Macias J; Pinilla A; Lao-Dominguez FA; Corma A; Contreras-Macias E; Gonzalez-Serna A; Gutierrez-Pizarraya A; Fernandez-Fuertes M; Morillo-Verdugo R; Trigo M; Real LM; Pineda JA Sci Rep 2020[Dec]; 10 (1): 20958 PMID33262433show ga The impact of drug-drug interactions (DDI) between ritonavir-boosted lopinavir (LPV-r) to treat patients with coronavirus disease 2019 (COVID-19) and commonly used drugs in clinical practice is not well-known. Thus, we evaluated the rate and severity of DDI between LPV-r for COVID-19 treatment and concomitant medications. This was a cross-sectional study including all individuals diagnosed of SARS-CoV-2 infection treated with LPV-r and attended at a single center in Southern Spain (March 1st to April 30th, 2020). The frequency [95% confidence interval (95% CI)] of potential and major DDI were calculated. Overall, 469 patients were diagnosed of COVID-19, 125 (27%) of them were prescribed LPV-r. LPV-r had potential DDI with concomitant medications in 97 (78%, 95% CI 69-85%) patients, and in 33 (26%, 95% CI 19-35%) individuals showed major DDI. Twelve (36%) patients with major DDI and 14 (15%) individuals without major DDI died (p = 0.010). After adjustment, only the Charlson index was independently associated with death [adjusted OR (95% CI) for Charlson index >/= 5: 85 (10-731), p < 0.001]. LPV-r was discontinued due to side effects in 31 (25%) patients. Management by the Infectious Diseases Unit was associated with a lower likelihood of major DDI [adjusted odds ratio (95% CI): 0.14 (0.04-0.53), p = 0.003). In conclusion, a high frequency of DDI between LPV-r for treating COVID-19 and concomitant medications was found, including major DDI. Patients with major DDI showed worse outcomes, but this association was explained by the older age and comorbidities. Patients managed by the Infectious Diseases Unit had lower risk of major DDI. |*COVID-19 Drug Treatment[MESH] |Aged[MESH] |Antiviral Agents/*adverse effects/therapeutic use[MESH] |Cross-Sectional Studies[MESH] |Drug Combinations[MESH] |Drug Interactions[MESH] |Female[MESH] |Humans[MESH] |Lopinavir/*adverse effects/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Protease Inhibitors/*adverse effects/therapeutic use[MESH] |Ritonavir/*adverse effects/*therapeutic use[MESH] |SARS-CoV-2/drug effects[MESH]High rate of major drug-drug interactions of lopinavir-ritonavir for C(epmc).pdf DeepDyve Pubget Overpricing